Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL

CAMBRIDGE, Massachusetts—Biogen Idec has initiated a randomized, multicenter, registration trial, known as LUCID, of its anti-CD23 monoclonal antibody lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab (FCR) vs FCR alone for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The antibody was also granted Fast Track and Orphan Drug designation by FDA. In a phase I/II trial reported at the 2006 ASH Annual Meeting, the addition of lumiliximab to the FCR regimen resulted in a 52% complete response rate among CLL patients with progressive disease, the company said.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content